Activity Prediction and Structural Insights of Extracellular Signal‐Regulated Kinase 2 Inhibitors with Molecular Dynamics Simulations

A computational application to predict, probe and interpret the activities of a series of congeneric compounds inhibiting extracellular signal‐regulated kinase 2 protein kinase is presented. The study shows that molecular dynamics coupled with molecular mechanics Poisson–Boltzmann solvent accessible surface area free energy estimation is a suitable tool for investigating the experimental binding activities of ligands to protein kinases. Computed and experimental binding activities were found to be significantly correlated. Moreover, the interpretation of the X‐ray co‐crystal structure in conjunction with computational results shows that the hinge region of the protein insure the principal binding site via multiple hydrogen bonding interactions, whereas fine‐modulation of biological activities along the series is accomplished through the combination of weak and strong interactions that compete with water. These are located in the substituent moieties of the ligands interfacing with the DFG motif, the sugar region and the hydrophobic pocket of extracellular signal‐regulated kinase 2. The study suggests that a wider interaction framework that is well beyond the hinge region is required to predict and rationalize at molecular level the experimental biological activities of congeneric compound series.

[1]  J Downward,et al.  Interaction of Ras and Raf in intact mammalian cells upon extracellular stimulation. , 1994, The Journal of biological chemistry.

[2]  E. Goldsmith,et al.  Mutation of position 52 in ERK2 creates a nonproductive binding mode for adenosine 5'-triphosphate. , 1996, Biochemistry.

[3]  E. Goldsmith,et al.  Structural basis of inhibitor selectivity in MAP kinases. , 1998, Structure.

[4]  P. Kollman,et al.  Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. , 2001, Journal of the American Chemical Society.

[5]  A. Bridges,et al.  Chemical inhibitors of protein kinases. , 2001, Chemical reviews.

[6]  L. Johnson,et al.  Protein Kinase Inhibitors: Insights into Drug Design from Structure , 2004, Science.

[7]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[8]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[9]  Kevan M Shokat,et al.  Features of selective kinase inhibitors. , 2005, Chemistry & biology.

[10]  Ken Garber,et al.  The second wave in kinase cancer drugs , 2006, Nature Biotechnology.

[11]  U. Ryde,et al.  Ligand affinities predicted with the MM/PBSA method: dependence on the simulation method and the force field. , 2006, Journal of Medicinal Chemistry.

[12]  Paul D Lyne,et al.  Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. , 2006, Journal of medicinal chemistry.

[13]  A. Ferrari,et al.  Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors. , 2007, Bioorganic & medicinal chemistry.

[14]  Xiaoling Xie,et al.  Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors. , 2007, Journal of medicinal chemistry.

[15]  L. Amzel,et al.  Compensating Enthalpic and Entropic Changes Hinder Binding Affinity Optimization , 2007, Chemical biology & drug design.

[16]  M. Gilson,et al.  Calculation of protein-ligand binding affinities. , 2007, Annual review of biophysics and biomolecular structure.

[17]  Are MAP Kinases Drug Targets? Yes, but Difficult Ones , 2007, ChemMedChem.

[18]  S. Knapp,et al.  A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases , 2007, Proceedings of the National Academy of Sciences.

[19]  Steven W. Muchmore,et al.  Rapid Estimation of Relative Protein-Ligand Binding Affinities Using a High-Throughput Version of MM-PBSA , 2007, J. Chem. Inf. Model..

[20]  W. El-Deiry,et al.  ERK and MDM2 prey on FOXO3a , 2008, Nature Cell Biology.

[21]  J. Zou,et al.  Effect of mutation K85R on GSK-3beta: Molecular dynamics simulation. , 2008, Biochemical and biophysical research communications.

[22]  Giulio Rastelli,et al.  Molecular modeling and crystal structure of ERK2-hypothemycin complexes. , 2008, Journal of structural biology.

[23]  G. Degliesposti,et al.  Binding Estimation after Refinement, a New Automated Procedure for the Refinement and Rescoring of Docked Ligands in Virtual Screening , 2009, Chemical biology & drug design.

[24]  Allan Wissner,et al.  Kinase domain mutations in cancer: implications for small molecule drug design strategies. , 2009, Journal of medicinal chemistry.

[25]  Giulio Rastelli,et al.  Fast and accurate predictions of binding free energies using MM‐PBSA and MM‐GBSA , 2009, J. Comput. Chem..